S-100 serum levels after minor and major head injury.

BACKGROUND S-100, a protein of astroglial cells, is described as a marker for central nervous system damage. The aim of this study was to evaluate whether the marker could give information about the severity and possibility of functional recovery after minor and severe head injury. METHODS Thirty patients after severe head injury (Glasgow Coma Scale score < 9) and 11 patients after minor head injury (Glasgow Coma Scale score > 12) were included. In each case, blood samples were drawn within 6 hours after injury. Outcome was estimated at hospital discharge using the Glasgow Outcome Scale. RESULTS All patients who sustained minor head injury had reached a favorable outcome by the time they were discharged from the hospital. Their mean S-100 serum level was 0.35 microg/L. Patients who sustained severe head injury and were classified as having an unfavorable outcome (31%) showed a mean serum concentration of 4.9 microg/L, whereas patients classified as having a favorable outcome (69%) had a mean S-100 level of 1.2 microg/L. All groups differed significantly (p < 0.05). CONCLUSION S-100 appears to be a promising marker for the severity of head injury and neuronal damage.

[1]  B. Romner,et al.  Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury. Case report. , 1996, Journal of neurosurgery.

[2]  T. Ohwada,et al.  Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. , 1995, Surgical neurology.

[3]  W. Schlote,et al.  Neuron-specific enolase in gerbil brain and serum after transient cerebral ischemia. , 1995, Stroke.

[4]  F. Barone,et al.  Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia , 1993, Brain Research.

[5]  S. Mckinstry,et al.  Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction , 1991, European journal of clinical investigation.

[6]  Y. Olsson,et al.  S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. , 1989, Journal of neurosurgery.

[7]  H. Nozaki,et al.  Neuron-specific enolase in comatose children. , 1988, American journal of diseases of children.

[8]  H. Hårdemark,et al.  S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. , 1987, Stroke.

[9]  G. Davies-Jones,et al.  Cerebrospinal fluid enolase in stroke. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[10]  F. Goodwin,et al.  MEASUREMENT OF NEURON‐SPECIFIC (NSE) AND NON‐NEURONAL (NNE) ISOENZYMES OF ENOLASE IN RAT, MONKEY AND HUMAN NERVOUS TISSUE , 1979, Journal of neurochemistry.

[11]  Foss Mv MANAGEMENT OF VIRUS HEPATITIS. , 1964 .